SCHEMBL333262

SCHEMBL333262

CC(C)[C@@H]1CC[C@@]2(C)CCC[C@H](C)[C@@H]2C1

nearest known ligand 0.32

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CDK5 Q00535 1/20 0.32
CDK5R1 Q15078 1/20 0.32
NR1I3 Q14994 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29604207 1.00 CDK5 (0.32) CDK5CDK5R1NR1I3
SCHEMBL333147 1.00 CDK5 (0.32) CDK5CDK5R1NR1I3
SCHEMBL6543134 0.81 GRIN1 (0.34) NR1I3
SCHEMBL3890866 0.80 AKR1B10 (0.33) NR1I3
SCHEMBL29637260 0.75
SCHEMBL16774422 0.75
SCHEMBL11672814 0.74 NR1I3 (0.50) CDK5CDK5R1NR1I3
SCHEMBL11671836 0.74 NR1I3 (0.50) CDK5CDK5R1NR1I3
SCHEMBL11671840 0.74 NR1I3 (0.50) CDK5CDK5R1NR1I3
SCHEMBL11673103 0.74 NR1I3 (0.50) CDK5CDK5R1NR1I3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 941 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118745189-B Guaiane-eudesman sesquiterpene dimer and preparation method and application thereof 中国科学院昆明植物研究所 2025-05-16 CN claimed
CN-118745189-A Guaiane-eudesman sesquiterpene dimer and preparation method and application thereof 中国科学院昆明植物研究所 2024-10-08 CN claimed
US-20240324588-A1 ESSENTIAL OIL MICROPARTICLES FOR POWDER COATING APPLICATIONS Genesee Valley Innovations, LLC 2024-10-03 US claimed
CN-118717754-A Lipid lowering application of 3 beta-angeloyloxy-4 alpha, 8 beta-dihydroxyl-eudesman-7 (11) -alkene-12, 8 alpha-lactone 大理大学 2024-10-01 CN claimed
CN-118717747-A Dodelate C lipid lowering application 大理大学 2024-10-01 CN claimed
CN-118702658-A Dobinin C and preparation and lipid-lowering application of acylated derivative thereof 大理大学 2024-09-27 CN claimed
CN-118652230-A Eucalyptus type sesquiterpene dimer compound and preparation method and application thereof 西南大学 2024-09-17 CN claimed
CN-118324734-A A series of eudesmane sesquiterpenoids in herba Artemisiae Annuae, and its preparation method and application 中国科学院新疆理化技术研究所 2024-07-12 CN claimed
CN-115583981-B Eucalyptus alkane type sesquiterpene glycoside compound, erythrina ovalifolia extract containing compound and application of compound 西北农林科技大学 2024-04-12 CN claimed
CN-116947794-B Eucalyptus type sesquiterpenoids rearranged by four-ring system, preparation method and application thereof, pharmaceutical composition and application thereof 云南中医药大学 2023-11-28 CN claimed
WO-2008027515-A2 PHOSPHORUS-CONTAINING STABILIZERS FOR FLUOROOLEFINS E. I. DU PONT DE NEMOURS AND COMPANY (US) 2008-03-06 WO claimed
WO-2008027511-A1 EPOXIDE AND FLUORINATED EPOXIDE STABILIZERS FOR FLUOROOLEFINS E. I. DU PONT DE NEMOURS AND COMPANY (US) 2008-03-06 WO claimed
EP-1885728-A1 CONVERSION OF AMORPHA-4,11- DIENE TO ARTEMISININ AND ARTEMISININ PRECURSORS Amyris Biotechnologies, Inc. (US) 2008-02-13 EP claimed
WO-2007126760-A2 COMPOSITIONS COMPRISING IODOTRIFLUOROMETHANE AND STABILIZERS E. I. DU PONT DE NEMOURS AND COMPANY (US) 2007-11-08 WO claimed
CN-101050209-A Eudesmane type sesquiterpene lactone compound extracted from Carpesium macrocephalum and having antibacterial activity, and its application CT OF NON HARM PESTICIDE RES & (CN) 2007-10-10 CN claimed
CN-1951378-A Medical usage of 2beta-hydroxyilicicacid in inhibiting hepatitis B WENZHOU MEDICAL COLLEGE (CN) 2007-04-25 CN claimed
CN-1927197-A Medical use of 1beta-keto-5, 11(13)-diene eudesmane-12-acid for inhibiting hepatitis B virus WENZHOU MEDICAL COLLEGE (CN) 2007-03-14 CN claimed
CN-1923787-A Eudesmane type sesquiterpenes acid and application thereof UNIV ZHEJIANG (CN) 2007-03-07 CN claimed
WO-2006128126-A1 CONVERSION OF AMORPHA-4,11- DIENE TO ARTEMISININ AND ARTEMISININ PRECURSORS AMYRIS BIOTECHNOLOGIES, INC. (US) 2006-11-30 WO claimed
US-20060270863-A1 CONVERSION OF AMORPHA-4,11-DIENE TO ARTEMISININ AND ARTEMISININ PRECURSORS AMYRIS BIOTECHNOLOGIES (US) 2006-11-30 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270863-A1 CONVERSION OF AMORPHA-4,11-DIENE TO ARTEMISININ AND ARTEMISININ PRECURSORS SQLE, CYP4A11, DHPS CDK5 2063/4885CDK5R1 1221/4885NR1I3 920/4885
US-20240324588-A1 ESSENTIAL OIL MICROPARTICLES FOR POWDER COATING APPLICATIONS EXOSC9, EXOSC4, PHOSPHO1 CDK5 2484/4885CDK5R1 2432/4885NR1I3 2091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.